Top Page
Amur Minerals
(LSE:CRTX)
Amur Minerals (CRTX) vs. iShares MSCI United Kingdom ETF (EWC)
Amur Minerals Business Overview & Revenue Model
Amur Minerals Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 25.00K | 57.37K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -4.12K | 21.00K | 16.57K | 0.00 | 0.00 | -3.90K |
| EBITDA | -1.24M | -566.00K | -2.26M | -1.81M | -1.30M | -3.08M |
| Net Income | -1.28M | -607.00K | -9.65M | -2.45M | -1.54M | -2.08M |
Balance Sheet | ||||||
| Total Assets | 2.38M | 1.82M | 4.79M | 23.89M | 23.06M | 23.71M |
| Cash, Cash Equivalents and Short-Term Investments | 479.03K | 1.28M | 4.38M | 2.90M | 4.93M | 2.79M |
| Total Debt | 0.00 | 0.00 | 888.54K | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 583.34K | 341.00K | 662.00K | 765.65K | 832.07K | 771.06K |
| Stockholders Equity | 1.80M | 1.48M | 4.12M | 23.13M | 30.11M | 31.35M |
Cash Flow | ||||||
| Free Cash Flow | -1.19M | -961.00K | -2.77M | -2.99M | -1.40M | -2.12M |
| Operating Cash Flow | -1.19M | -933.00K | -2.77M | -2.73M | -1.10M | -1.68M |
| Investing Cash Flow | -91.96K | 2.33M | 34.93M | -511.00K | 6.04M | -5.18M |
| Financing Cash Flow | 0.00 | -67.00K | -31.45M | 968.00K | 0.00 | 9.89M |
Amur Minerals Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | £5.30M | -2.20 | -88.05% | ― | ― | ― | |
44 Neutral | £1.88M | -1.80 | -18.71% | ― | ― | ― | |
43 Neutral | £5.75M | -5.18 | -433.59% | ― | ― | ― | |
43 Neutral | £937.98K | -4.11 | 3.93% | ― | ― | ― | |
42 Neutral | £6.33M | -0.70 | -153.80% | ― | ― | -616.67% |
Amur Minerals Corporate Events
CRISM Therapeutics has published the results of an independent analysis of its shareholder register as at 31 December 2025, identifying five significant shareholders each holding at least 3% of its ordinary share capital, with CEO Andrew Webb the largest shareholder at 14.1%. The company also disclosed that, following its recent placing and retail offer completed in December 2025, former major shareholders Linista Group Inc. and Spreadex no longer hold disclosable stakes, signalling a reshaped investor base as CRISM advances its clinical development plans.
The most recent analyst rating on (GB:CRTX) stock is a Hold with a £9.50 price target. To see the full list of analyst forecasts on Amur Minerals stock, see the GB:CRTX Stock Forecast page.
CRISM Therapeutics Corporation announced the successful closure of its Retail Offer, raising £59,610 through the sale of 662,332 shares. The funds will support the progression of a Phase 2 clinical trial for irinotecan-ChemoSeed in glioblastoma patients, with dosing expected to begin in Q1 2026. The new shares will be admitted to the London Stock Exchange, increasing the company’s total voting rights to 51,735,266.
CRISM Therapeutics Corporation, a company involved in the healthcare and pharmaceuticals industry, has announced a retail offer to raise up to £100,000 through the issuance of new ordinary shares at 9 pence per share. This initiative is part of a broader strategy to fund its Phase 2 clinical trial of irinotecan-ChemoSeed for glioblastoma patients. The retail offer is available to UK investors and is coordinated by SP Angel Corporate Finance LLP. The completion of this offer is contingent upon the admission of the new shares to the AIM market of the London Stock Exchange.
CRISM Therapeutics Corporation has successfully raised £1,000,000 through an oversubscribed placing of new ordinary shares, which will fund the progression of its Phase 2 clinical trial for irinotecan-ChemoSeed in glioblastoma patients. The funds will support various operational and clinical trial costs, with the first patient dosing expected in Q1 2026. The placing reflects strong shareholder support and positions CRISM to advance its innovative cancer treatment technology, potentially impacting its market position and offering new opportunities for stakeholders.
CRISM Therapeutics Corporation has submitted an application to the FDA for Orphan Drug Designation for its irinotecan-ChemoSeed™ aimed at treating glioblastoma, a rare and aggressive brain cancer. This move is part of CRISM’s broader strategy to gain accelerated development and market access in the US and UK, leveraging the benefits of ODD status, which include market exclusivity and regulatory support. The company is also preparing for a Phase 2 clinical trial and exploring global regulatory collaborations to expedite access to its promising cancer treatment.
CRISM Therapeutics Corporation announced significant preclinical findings for its ChemoSeed platform in prostate cancer treatment, showing that sustained administration of docetaxel is more effective than current intermittent dosing methods. This development could enhance treatment efficacy with lower drug doses, reducing side effects. Additionally, CRISM has partnered with Ulster University through a prestigious doctoral award to further develop personalized treatment strategies, potentially accelerating the path to clinical trials and improving patient outcomes.